Probably stating the obvious here but it looks like the whole...

Probably stating the obvious here but it looks like the whole orphan drug game is going to become more familiar to the greater world over the next few years. With decreased margins, crossovers and increased competition around mainstream drug markets, the ability to not be dictated to and be able to still control a market appears to be appearing in many coy focus/strategy. This is probably one of the few remaining opportunities in pharm world to get some assurances regarding control. I hope whoever takes ANP products on their next journey is a company with this type of focus and that we see some of our unique products duly rewarded for the success they have had to date in development.